Manufacturing In the face of tariffs, FDA-approved drug manufacturing deals are shifting to Europe Pharmaceutical TechnologyIn 2025, biopharma companies increasingly invested in Europe-based contract manufacturing for FDA-approved drugs compared to US-based providers.ManufacturingRead full story pharminent April 7, 2026 (Last updated: April 7, 2026) Pharmaceutical Technology In 2025, biopharma companies increasingly invested in Europe-based contract manufacturing for FDA-approved drugs compared to US-based providers. ManufacturingRead full story Post navigation Previous: Sanofi Bispecific Scores in Asthma, Rhinosinusitis, but Eczema Bet Doesn’t Pay OffNext: CatalYm begins phase 2b trial of visugromab in second-line liver cancer treatment Related Stories Manufacturing Sandoz plans ‘vast and vertically integrated’ supply chain to support 100-biosimilar vision pharminent September 9, 2026 Manufacturing US puts $125m into personalised RNA therapy production pharminent September 2, 2026 Manufacturing Multispecifics are transforming the CDMO development architecture pharminent August 28, 2026